Urgent Surgery for Gastric Adenocarcinoma: A Study of the National Cancer Database

Fisher, Benjamin W.; Fluck, Marcus; Young, Katelyn; Shabahang, Mohsen; Blansfield, Joseph; Arora, Tania K.

doi:10.1016/j.jss.2019.07.073

Cited by 17 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results were obtained by Ignjatovic et al [ 10 ] who demonstrated a higher survival rate among patients who underwent curative resection if compared to those who underwent simple closure with omental patch (75.77 days vs 18 days). Also the oncologic value of the surgical procedure seems to be worsened by the emergency setting of these patients: Fisher et al [ 15 ] in their paper found that patients who underwent urgent surgery for gastric cancer had significantly worse quality resections with decreased lymph node retrieved and increased positive margins as well as increased 30 day and overall mortality if compared to patients undergoing elective surgery.…”

Section: Discussionmentioning

confidence: 99%

“…2. but none points out differences in survival between patients who underwent adjuvant chemotherapy and those who did not [5,7,15].…”

Section: Surgical Procedures and Outcomesmentioning

confidence: 97%

“…The mean survival time was 23 months ranging from 2 months for patients who underwent palliative surgery to 75 months for patients who underwent curative resection. Only three papers report data about adjuvant chemotherapy but none points out differences in survival between patients who underwent adjuvant chemotherapy and those who did not [ 5 , 7 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Perforated gastric cancer: a critical appraisal

et al. 2021

View full text Add to dashboard Cite

Gastric cancer perforation is a life-threatening condition that accounts for less than 5% of all gastric cancer patients and typically requires emergency surgery. However, preoperative diagnosis is difficult and management has a dual purpose: to treat peritonitis and to achieve a curative resection. The optimal surgical strategy is still unclear and prognosis remains poor. A search of the literature was performed using MEDLINE databases (Pubmed, EMBASE, Web of Science and Cochrane) using terms such as “perforated gastric cancer”, “perforated gastric cancer and surgery”, “perforated gastric tumour” and “gastric cancer perforated”. Case reports, other reviews, non-english written papers and papers written before 2010 were excluded. Eight articles published between 2010 and 2020 matched the inclusion criteria for this review. Perforated gastric cancer was more prevalent in elderly males. Distal stomach was most frequently involved. Preoperative diagnosis was uncommon. Mortality rates ranged from 2 to 46%. Patients able to receive an R0 resection demonstrated better long-term survival compared with patients who had simple closure procedures. Laparoscopic procedure was mentioned only in one study. In an emergency situation, curative RO resection should always be offered in patients without multiple adverse factors. A surgical strategy using laparoscopic local repair as first step of surgery to resolve the peritonitis followed by a radical open or laparoscopic gastrectomy with lymphadenectomy could be considered. A balance between emergency and oncological needs should drive the surgical choice on a case by case basis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…2. but none points out differences in survival between patients who underwent adjuvant chemotherapy and those who did not [5,7,15].…”

Section: Surgical Procedures and Outcomesmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Perforated gastric cancer: a critical appraisal

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Currently, surgery and chemotherapy are the most common strategies in treatment of GC [65]. However, the recurrence of GC usually occurs after surgery.…”

Section: Current Therapeutic Strategies Challenges and Future Prospective For Gastric Cancermentioning

confidence: 99%

Anti-tumor activity of resveratrol against gastric cancer: a review of recent advances with an emphasis on molecular pathways

et al. 2021

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the most common cancers with high malignancy. In spite of the great development in diagnostic tools and application of anti-tumor drugs, we have not witnessed a significant increase in the survival time of patients with GC. Multiple studies have revealed that Wnt, Nrf2, MAPK, and PI3K/Akt signaling pathways are involved in GC invasion. Besides, long non-coding RNAs and microRNAs function as upstream mediators in GC malignancy. GC cells have acquired resistance to currently applied anti-tumor drugs. Besides, combination therapy is associated with higher anti-tumor activity. Resveratrol (Res) is a non-flavonoid polyphenol with high anti-tumor activity used in treatment of various cancers. A number of studies have demonstrated the potential of Res in regulation of molecular pathways involved in cancer malignancy. At the present review, we show that Res targets a variety of signaling pathways to induce apoptotic cell death and simultaneously, to inhibit the migration and metastasis of GC cells.

show abstract

“…Several limitations should be concerned. First, this retrospective study design may have inherent selection bias, because the variables in our analysis are selected from previous data (17). Second, the patient comorbidities, chemotherapy regime, surgical margin status, and possible complications after surgery are not available in the SEER database (18).…”

Section: Stratified Analysismentioning

confidence: 99%

Adjuvant radiotherapy may have significant survival benefits for gastric cancer patients with 1-29 lymph nodes retrieved

Wu¹,

Chu²,

Hu³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: The role of adjuvant radiotherapy (RT) in gastric cancer (GC) patients has not been wellestablished. This study initiated a retrospective case-control study to explore the survival impact of adjuvant RT on these patients.Methods: All patients were collected from the Surveillance, Epidemiology, and End Results (SEER) database. The cohort was assigned into patients without adjuvant RT versus those with adjuvant RT.Descriptive chi-square test was adopted to compare categorical variates between the 2 groups. Kaplan-Meier (KM) method was adopted to estimate the patients' cancer-specific survival (CSS) and overall survival (OS).Cox proportional hazard models were utilized to characterize the prognostic factors of their CSS.Results: Totally 7,194 patients were recruited in this study, 3,326 (46.2%) patients didn't have RT and 3,868 (53.8%) patients had adjuvant RT. Survival analysis of the entire population showed that adjuvant RT had remarkable survival benefits for the GC patients. The median CSS was 47.0 (42.0-52.0) months in RT group versus 32.0 (29.7-34.3) months in no RT group (P<0.001). Age >60, histologic type 8490, tumor size >50 mm, higher stage TNM, and surgery type 40/50 were independent risk factors for poor prognosis.Comparatively, adjuvant RT and LN examined >0 were independent factors for improving prognosis.Subgroup analysis demonstrated that adjuvant RT had significant survival benefits for patients with 1-14 and 15-29 lymph nodes (LNs) retrieved.Conclusions: Adjuvant radiotherapy may have significant survival benefits for GC patients with 1-29 LNs retrieved. Our study upholds adjuvant RT for this subset of patients.

show abstract

Urgent Surgery for Gastric Adenocarcinoma: A Study of the National Cancer Database

Cited by 17 publications

References 23 publications

Perforated gastric cancer: a critical appraisal

Perforated gastric cancer: a critical appraisal

Anti-tumor activity of resveratrol against gastric cancer: a review of recent advances with an emphasis on molecular pathways

Adjuvant radiotherapy may have significant survival benefits for gastric cancer patients with 1-29 lymph nodes retrieved

Contact Info

Product

Resources

About